Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neuroblastoma suppressor of tumorigenicity 1 is a circulating protein associated with progression to end-stage kidney disease in diabetes

10 Aug 2022

Abstract excerpt

Circulating proteins associated with transforming growth factor-β (TGF-β) signaling are implicated in the development of diabetic kidney disease (DKD). It remains to be comprehensively examined which of these proteins are involved in the pathogenesis of DKD and its progression to end-stage kidney disease (ESKD) in humans. Using the SOMAscan proteomic platform, we measured concentrations of 25 TGF-β signaling...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Metabolism, Diabetes, and Cancer
Share to Pancreatic and Hepatic Oncology Research
Share to Parathyroid Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35947673
DOI: 10.1126/scitranslmed.abj2109

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neuroblastoma suppressor of tumorigenicity 1 is a circulating protein associated with progression to end-stage kidney disease in diabetesPMID 35947673Read ↗

Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetesSemantic proximity Read ↗

Circulating proteins linked to apoptosis processes and fast development of end-stage kidney disease in diabetesSemantic proximity Read ↗

Comprehensive Search for Novel Circulating miRNAs and Axon Guidance Pathway Proteins Associated with Risk of ESKD in DiabetesSemantic proximity Read ↗

Multiomics Analyses Identify AKR1A1 as a Biomarker for Diabetic Kidney DiseaseSemantic proximity Read ↗

Proteonano™: a novel deep proteomics platform with 1000-plex profiling capacity and picogram sensitivity and its application in diabetic kidney diseaseSemantic proximity Read ↗

CTSS and CD53: Emerging m6A methylation markers in diabetic kidney disease pathogenesis and their clinical implicationsSemantic proximity Read ↗

NBL1 associates with renal phenotypes in mice, but partial Nbl1 reduction does not ameliorate kidney disease.Semantic proximity Read ↗

Plasma Proteomics of Diabetic Kidney Disease Among Asians With Younger-Onset Type 2 DiabetesSemantic proximity Read ↗

Biomarker panels associated with progression of renal disease in type 1 diabetesSemantic proximity Read ↗

Unbiased Human Kidney Tissue Proteomics Identifies Matrix Metalloproteinase 7 as a Kidney Disease BiomarkerSemantic proximity Read ↗

Low circulating miR-190a-5p predicts progression of chronic kidney disease.Semantic proximity Read ↗

Trajectories of kidney function in diabetes: a clinicopathological update.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.